Table 5.
Termination results based on the wild-type and PITX2+/− deficiency.
| Termination | ||||
|---|---|---|---|---|
| Overall (n = 500) | Wild type(n = 250) | PITX2+/− deficiency (n = 250) | p-value | |
| Class IC + Class III (n = 500) | 180/500 (36.0%) | 86/250 (34.4%) | 94/250 (37.6%) | 0.514 |
| Class IC (n = 200) | 38/200 (19.0%) | 12/100 (12.0%) | 26/100 (26.0%) | 0.018 |
| Flecainide 5 μM (n, %) | 6 (12.0%) | 2 (8.0%) | 4 (16.0%) | – |
| Flecainide 15 μM (n, %) | 11 (22.0%) | 4 (16.0%) | 7 (28.0%) | – |
| Propafenone 5 μM (n, %) | 8 (16.0%) | 3 (12.0%) | 5 (20.0%) | – |
| Propafenone 10 μM (n, %) | 13 (26.0%) | 3 (12.0%) | 10 (40.0%) | – |
| Class III (n = 300) | 131/300 (43.7%) | 66/150 (44.0%) | 65/150 (43.3%) | 1.000 |
| Amiodarone 5 μM (n, %) | 21 (42.0%) | 10 (40.0%) | 11 (44.0%) | – |
| Amiodarone 10 μM (n, %) | 27 (54.0%) | 16 (64.0%) | 11 (44.0%) | – |
| Sotalol 60 μM (n, %) | 12 (24.0%) | 4 (16.0%) | 8 (32.0%) | – |
| Sotalol 10 mM (n, %) | 26 (52.0%) | 9 (36.0%) | 17 (68.0%) | – |
| Dronedarone 3 μM (n, %) | 22 (44.0%) | 11 (44.0%) | 11 (44.0%) | – |
| Dronedarone 10 μM (n, %) | 23 (46.0%) | 16 (64.0%) | 7 (28.0%) | – |
n, number of patient *AAD*dose.